ReoPro anti-platelet antibody: Update

Primary end point in the trial is death, myocardial infarction and urgent intervention at 30 days. Dose is an 0.25 mg/kg 10-60 minute bolus prior to angioplasty, followed by

Read the full 290 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE